Key result
Five upregulated hub genes differentiate advanced from mild NAFLD fibrosis with an AUC over 0.7.
Why the study?
The mechanism underlying NASH development and liver fibrosis progression in NAFLD remains unclear, hindering early screening and intervention.
Observational (n=243)
Effect estimate: AUC > 0.7
BICC1, C7, EFEMP1, LUM, and STMN2 were identified as potential hub gene targets for early screening and treatment of NASH.
These hub genes are hypothesis-generating in NASH; prospective validation required before any screening or therapeutic role.
Nonalcoholic fatty liver disease (NAFLD) is a common type of chronic liver disease, with severity levels ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH). The extent of liver fibrosis indicates the severity of NASH and the risk of liver cancer. However, the mechanism underlying NASH development, which is important for early screening and intervention, remains unclear. Weighted gene co-expression network analysis (WGCNA) is a useful method for identifying hub genes and screening specific targets for diseases. In this study, we utilized an mRNA dataset of the liver tissues of patients with NASH and conducted WGCNA for various stages of liver fibrosis. Subsequently, we employed two additional mRNA datasets for validation purposes. Gene set enrichment analysis (GSEA) was conducted to analyze gene function enrichment. Through WGCNA and subsequent analyses, complemented by validation using two additional datasets, we identified five genes (BICC1, C7, EFEMP1, LUM, and STMN2) as hub genes. GSEA analysis indicated that gene sets associated with liver metabolism and cholesterol homeostasis were uniformly downregulated. BICC1, C7, EFEMP1, LUM, and STMN2 were identified as hub genes of NASH, and were all related to liver metabolism, NAFLD, NASH, and related diseases. These hub genes might serve as potential targets for the early screening and treatment of NASH.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2023) conducted an observational in Nonalcoholic fatty liver disease (n=243). Advanced liver fibrosis (stages 3-4) vs. Mild liver fibrosis (stages 0-1) was evaluated on Identification of hub genes differentiating advanced from mild liver fibrosis (AUC > 0.7). Five hub genes (BICC1, C7, EFEMP1, LUM, and STMN2) were consistently upregulated in advanced NAFLD and differentiated advanced from mild liver fibrosis with an AUC greater than 0.7.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: